Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000578 | 0.86 | SMYD2 (0.34) | SMYD2ROCK2MCHR1 | |
| SCHEMBL3747442 | 0.78 | SMYD2 (0.40) | SMYD2 | |
| SCHEMBL2993811 | 0.77 | PER2 (0.40) | SMYD2 | |
| SCHEMBL3982182 | 0.77 | DHPS (0.34) | SMYD2 | |
| SCHEMBL3806266 | 0.75 | F10 (0.36) | — | |
| SCHEMBL2993254 | 0.75 | F10 (0.43) | — | |
| SCHEMBL2993251 | 0.75 | F10 (0.43) | — | |
| SCHEMBL25209725 | 0.74 | CHRM4 (0.38) | SMYD2 | |
| SCHEMBL2994186 | 0.72 | MCHR1 (0.36) | MCHR1 | |
| SCHEMBL23670531 | 0.68 | SMYD2 (0.43) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| EP-2167495-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155034-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | SMYD2 4461/4885ROCK2 4391/4885MCHR1 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.